Why insider trading matters?

If management teams do not own any relevant stakes in the companies they guide, they may not be focused on creating wealth for shareholders to the same degree, compared to those that see their personal wealth increase when share prices rise.

- Klaus Gugler, Economist
NOVAVAX INC (NVAX)
Sector: Healthcare; Industry: Biotechnology

Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate that in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase III clinical trial for treating seasonal influenza in older adults. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2021-05-07 Trizzino John EVP, CCO, CBO & Interim CFO Sell 3,212 $184.94 $594,030 Yes
2021-04-30 Herrmann John A III EVP, Chief Legal Officer Sell 2,895 $239.83 $694,317 Yes
2021-04-19 Glenn Gregory M President, R&D Sell 8,129 $206.11 $1,675,439 Yes
2021-04-07 Trizzino John EVP, Chief Commercial Officer Sell 3,212 $189.38 $608,296 Yes
2021-03-26 Herrmann John A III EVP, Chief Legal Officer Sell 2,894 $186.80 $540,609 Yes
2021-03-25 YOUNG JAMES F Director Sell 10,000 $228.22 $2,282,231 Yes
2021-03-19 MCMANUS MICHAEL A JR Director Sell 4,000 $220.78 $883,110 No
2021-03-15 EVANS GARY C Director Sell 24,500 $211.21 $5,174,536 Yes
2021-03-17 Glenn Gregory M President, R&D Sell 8,135 $204.63 $1,664,704 Yes
2021-03-09 Trizzino John EVP, Chief Commercial Officer Sell 3,211 $163.74 $525,761 Yes
2021-02-26 Herrmann John A III EVP, Chief Legal Officer Sell 2,895 $225.48 $652,759 Yes
2021-02-18 Glenn Gregory M President, R&D Sell 2,434 $269.57 $656,134 No
2021-02-16 Glenn Gregory M President, R&D Sell 5,712 $282.71 $1,614,812 Yes
2021-02-09 Trizzino John EVP, Chief Commercial Officer Sell 3,216 $292.51 $940,719 Yes
2021-02-01 Herrmann John A III EVP, Chief Legal Officer Sell 15,022 $241.50 $3,627,789 Yes
2021-01-25 Trizzino John EVP, Chief Commercial Officer Sell 73 $128.60 $9,388 No
2021-01-07 Trizzino John EVP, CMO and CBO Sell 17,913 $112.34 $2,012,353 Yes
2020-12-31 YOUNG JAMES F Director Sell 11,000 $113.09 $1,244,014 Yes
2020-11-16 Erck Stanley C President and CEO Sell 52,316 $90.65 $4,742,667 Yes
2020-09-30 Trizzino John EVP, CBO and CFO Sell 2,250 $110.22 $248,002 No
2020-10-01 Erck Stanley C President and CEO Sell 12,233 $110.23 $1,348,418 No
2020-09-29 Herrmann John A III EVP, Chief Legal Officer Sell 42,779 $109.04 $4,664,546 Yes
2020-09-29 Glenn Gregory M President, R&D Sell 44,949 $108.84 $4,892,300 Yes
2020-09-29 Trizzino John EVP, CBO and CFO Sell 43,321 $109.03 $4,723,086 Yes
2020-09-29 Erck Stanley C President and CEO Sell 29,112 $109.95 $3,200,722 Yes
2020-08-18 Trizzino John EVP, CBO and CFO Sell 42,788 $148.78 $6,366,182 Yes
2020-08-18 MCMANUS MICHAEL A JR Director Sell 8,000 $146.00 $1,168,000 Yes
2020-08-18 Herrmann John A III EVP, Chief Legal Officer Sell 46,242 $144.33 $6,673,982 Yes
2020-08-18 Glenn Gregory M President, R&D Sell 55,921 $145.20 $8,119,860 Yes
2020-08-18 EVANS GARY C Director Sell 10,500 $150.44 $1,579,620 Yes

Insider Smart

Edesa Biotech, Inc. (EDSA) - President and CEO bought shares of EDSA in late May around $3, two weeks after their purchase, the stock jump to $9, very well timed buy.

Insider Smart

Ovintiv Inc (OVV) - Insiders of OVV have been HEAVILY accumulating shares in March with a sub-$3 cost. And the stock is now $11. An awesome 400% gain can't be missed if you found it was heavily accumulated earlier.